Switching from Bupropion (Wellbutrin) to Vortioxetine
Recommended Cross-Taper Protocol
The safest method is to taper bupropion to 150 mg daily for 3–7 days while simultaneously initiating vortioxetine 10 mg daily, then discontinue bupropion and continue vortioxetine. 1
Step-by-Step Switching Algorithm
Days 1–3:
- Continue current bupropion dose
- Start vortioxetine 10 mg once daily in the morning 2
- This brief overlap maintains antidepressant coverage and reduces relapse risk 1
Days 4–7:
- Reduce bupropion to 150 mg once daily (if patient was on 300 mg) 3
- Continue vortioxetine 10 mg daily 2
- This gradual taper minimizes discontinuation symptoms while establishing vortioxetine therapy 1
Day 8 onward:
- Discontinue bupropion completely 3
- Continue vortioxetine 10 mg daily 2
- Consider forced up-titration to vortioxetine 20 mg daily after 1 week if tolerated and clinically indicated 4
Pharmacologic Rationale for This Approach
- Bupropion lacks serotonergic activity, eliminating any risk of serotonin syndrome when overlapped with vortioxetine during the cross-taper 1
- Vortioxetine has minimal cytochrome P450 interactions, allowing safe concurrent use with bupropion during the transition period 2
- Cross-titration was well-tolerated in clinical studies, with generally mild side effects during the changeover period and mean depression scores improving by 2.5 points within the first 2 weeks 2
Critical Safety Monitoring During Weeks 1–2
Neuropsychiatric surveillance must include:
- Suicidal ideation or worsening depression 1
- Agitation, irritability, or akathisia 1
- Unusual behavioral changes, hostility, or impulsivity 1
- New-onset anxiety or panic symptoms 1
Bupropion discontinuation symptoms to monitor:
- Insomnia or sleep disturbances 5
- Irritability or mood changes 1
- Headache or dizziness 5
- Fatigue (though this may improve with vortioxetine) 1
Expected Timeline for Vortioxetine Response
- Week 2: Mean reduction in depression severity of 2.5 points on MADRS scale 2
- Week 4: Additional 2.5-point reduction in MADRS score 2
- Week 8: Response rates (≥50% symptom reduction) of 61% for depression and 55% for anxiety; remission rates of 35% for depression and 42% for anxiety 4
Vortioxetine Dosing Strategy
Initial dose: 10 mg once daily in the morning 2, 4
Dose escalation: Consider forced up-titration to 20 mg daily after 1 week of treatment, which has been shown to be well-tolerated and may provide superior efficacy in patients with severe depression or comorbid anxiety 4
Maximum dose: 20 mg daily 4
Clinical Advantages of Switching to Vortioxetine
- Superior remission rates compared to agomelatine (11% absolute risk difference) and numerically higher remission rates than sertraline, venlafaxine, and bupropion in switch studies 6
- Significantly lower withdrawal rates due to adverse events compared to sertraline (12.1% lower), venlafaxine XR (12.3% lower), and bupropion SR (18.3% lower) 6
- Marked improvements in cognitive function (SMD = 1.86) and functional disability (SMD = 1.71) in real-world studies 7
- Effective for comorbid anxiety: 55% response rate and 42% remission rate for anxiety symptoms in patients with MDD and comorbid GAD 4
- Lower sexual dysfunction rates compared to SSRIs, making it a preferred option when sexual side effects are a concern 8
When This Switch Is Most Appropriate
Strongly consider switching from bupropion to vortioxetine when:
- Patient experiences inadequate response to bupropion after 6–8 weeks at therapeutic dose 1
- Comorbid anxiety symptoms require treatment, as vortioxetine demonstrates dual efficacy for depression and anxiety 4
- Cognitive symptoms (concentration, memory, executive function) are prominent, as vortioxetine shows significant cognitive benefits 7
- Patient has agitated depression, since bupropion's activating properties may worsen agitation 5
- Insomnia is problematic, as bupropion's stimulant effects can interfere with sleep 5, 1
Common Pitfalls to Avoid
Do not abruptly discontinue bupropion at doses of 300 mg daily; taper to 150 mg for several days before stopping to minimize discontinuation symptoms 3
Do not delay vortioxetine initiation waiting for complete bupropion washout; the cross-taper approach is safer and maintains continuous antidepressant coverage 1, 2
Do not underdose vortioxetine; consider early up-titration to 20 mg daily after 1 week if the patient tolerates 10 mg, as higher doses may provide superior efficacy without compromising tolerability 4
Do not expect immediate response; allow a full 4–8 weeks at therapeutic dose before concluding vortioxetine is ineffective 1